Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Cytopathology|December 27, 2022
Small volume biopsy diagnostic yield at initial diagnosis versus recurrence/transformation of follicular lymphoma: A retrospective Cyto-Heme Interinstitutional Collaborative studyMegan J Fitzpatrick, Vandana Sundaram, Amy Ly, et al.
Leukemia & Lymphoma|June 28, 2021
Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformationEric Mou, Lorenzo Falchi, Vandana Sundaram, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.
Blood Advances|February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort StudyJia Ruan, Zhengming Chen, Melissa C Larson, et al.
Blood|April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with ImmunochemotherapyProkop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Blood|December 2, 2025
Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP studyAndrew L Feldman, Surendra Dasari, Lisa M Rimsza, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 3